País: Canadá
Idioma: inglés
Fuente: Health Canada
MOXIFLOXACIN (MOXIFLOXACIN HYDROCHLORIDE)
PHARMASCIENCE INC
J01MA14
MOXIFLOXACIN
400MG
TABLET
MOXIFLOXACIN (MOXIFLOXACIN HYDROCHLORIDE) 400MG
ORAL
100
Prescription
QUINOLONES
Active ingredient group (AIG) number: 0142242001; AHFS:
APPROVED
2015-12-21
_ _ _pms-MOXIFLOXACIN Product Monograph _ _Page 1 of 69 _ PRODUCT MONOGRAPH PR PMS-MOXIFLOXACIN Moxifloxacin Tablets 400 mg (as moxifloxacin hydrochloride) ANTIBACTERIAL AGENT PHARMASCIENCE INC. DATE OF REVISION: 6111 Royalmount Avenue, Suite 100 May 9, 2019 Montréal, Canada H4P 2T4 www.pharmascience.com SUBMISSION CONTROL NO: 225692 _ _ _pms-MOXIFLOXACIN Product Monograph _ _Page 2 of 69 _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ........................................................ 3 SUMMARY PRODUCT INFORMATION ................................................................................ 3 INDICATIONS AND CLINICAL USE ..................................................................................... 3 CONTRAINDICATIONS .......................................................................................................... 6 WARNINGS AND PRECAUTIONS ......................................................................................... 6 ADVERSE REACTIONS ......................................................................................................... 15 DRUG INTERACTIONS ......................................................................................................... 19 DOSAGE AND ADMINISTRATION ..................................................................................... 21 OVERDOSAGE ....................................................................................................................... 22 ACTION AND CLINICAL PHARMACOLOGY .................................................................... 23 STORAGE AND STABILITY ................................................................................................. 31 SPECIAL HANDLING INSTRUCTIONS ............................................................................... 31 DOSAGE FORMS, COMPOSITION AND PACKAGING ..................................................... 31 PART II: SCIENTIFIC INFORMATION .............................................................................. 32 PHARMACEU Leer el documento completo